Liver News and Research

RSS

Women face higher risk of graft loss after liver transplantation compared to men

Although women with chronic hepatitis C virus (HCV) infection are at lower risk for developing cirrhosis, researchers who compared outcomes for men and women after having liver transplantation found that women have a significantly increased risk of overall graft loss and graft loss from recurrent HCV than men.

30 Oct 2009

Study shows how differing Asian cultures and attitudes impact cancer screening rates

The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander."

30 Oct 2009

Varian Medical Systems to showcase future technologies for managing cancer at the ASTRO

New technology enhancements from Varian Medical Systems, designed to make radiotherapy and radiosurgery treatments faster, more accurate, and easier to plan and deliver, will be on display at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago next week.

29 Oct 2009

Publix Supermarkets to sell HeartSavior and LipidShield Plus

New Health Corp. is proud to announce that HeartSavior(TM) and LipidShield® Plus are now available at Publix Supermarkets.

29 Oct 2009

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

Today is World Psoriasis Day and the National Psoriasis Foundation is asking all Americans affected by psoriasis and psoriatic arthritis to raise awareness about these diseases by going to www.psoriasis.org/wpd and taking action.

29 Oct 2009

Repros Therapeutics amends its existing license for Proellex

Repros Therapeutics today announced that the Company has entered into an amendment with the National Institutes of Health (NIH) to its existing exclusive license for Proellex® that revises the existing milestones and dates for performance to provide additional time to lift the current clinical hold on Proellex or select a second generation molecule for further development from the family of anti-progestational agents covered by the license.

29 Oct 2009

Supportive data from a preclinical study of SCY-635 to be presented

Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009.

29 Oct 2009

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

The human body contains billions of microorganisms, and microbial cells found in the human gut are estimated to outnumber human cells by ten-to-one in healthy adults. However, little is known about the ways in which these minute life forms influence health and disease.

28 Oct 2009

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Serial No. 10/909,125).

28 Oct 2009

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.

28 Oct 2009

Multidisciplinary center to be launched for treatment of advanced liver disease

Distinguished transplant and cancer surgeon, Alan Hemming, MD, has been recruited to the University of California, School of Medicine to launch a multidisciplinary center for the treatment of advanced liver disease at the UC San Diego Medical Center and Moores UCSD Cancer Center.

28 Oct 2009

NCI grant to conduct innovative cancer research

A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.

28 Oct 2009

More people rely on alternative medicine

As consumers look to save money in a tough economy, many turn to alternative health care options. CBS 4 reports: "Health care costs are soaring. Thousands of people are without jobs and without the benefits afforded them. Now, those people are turning to preventative or alternative measures. ... The National Center for Complimentary and Alternative Medicine (NCCAM) shows 38 percent of adults and 12 percent of kids are now using alternative therapies to treat pain. In fact, Americans are now reportedly spending $34 billion a year on alternative therapies" (Demos, 10/26).

27 Oct 2009

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Celsion Corporation and Yakult Honsha Co., Ltd. announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

27 Oct 2009

CryoLife granted FDA approval for BioFoam human clinical trial

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology.

27 Oct 2009

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

BioSphere Medical, Inc. – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.

27 Oct 2009

Positive results from Phase II clinical trial of INT-747 announced

Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC).

27 Oct 2009

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

Edmonton - Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone, Dr. Christian Constance told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

27 Oct 2009

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

Building on the strengths of two institutions separated by nearly 9,000 miles over two continents - both renowned in their work in the fight against cancer - the United States Agency for International Development has awarded a $500,000 grant to Fred Hutchinson Cancer Research Center to aid in the construction of the first American cancer clinic and medical-training facility in Africa.

27 Oct 2009

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers.

27 Oct 2009

Liver News and Research

Women face higher risk of graft loss after liver transplantation compared to men

Study shows how differing Asian cultures and attitudes impact cancer screening rates

Varian Medical Systems to showcase future technologies for managing cancer at the ASTRO

Publix Supermarkets to sell HeartSavior and LipidShield Plus

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

Repros Therapeutics amends its existing license for Proellex

Supportive data from a preclinical study of SCY-635 to be presented

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

Multidisciplinary center to be launched for treatment of advanced liver disease

NCI grant to conduct innovative cancer research

More people rely on alternative medicine

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

CryoLife granted FDA approval for BioFoam human clinical trial

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

Positive results from Phase II clinical trial of INT-747 announced

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News